Navigation Links
Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising interim Phase 2a data
Date:11/2/2013

ntly completed patient enrollment for its Phase 3 clinical trials, HCVerso®1 and 2 (NCT01732796, NCT01728324), which investigate the efficacy and safety of the investigational compounds, faldaprevir and deleobuvir, in combination with ribavirin. These trials evaluate genotype-1b HCV patients, including difficult-to-treat populations such as those who are ineligible for interferon and those with liver disease including cirrhosis. 

Faldaprevir, deleobuvir, and PPI-668 are investigational compounds and not approved. Their safety and efficacy have not been fully established.

About Boehringer Ingelheim in Hepatitis C Virus (HCV)
In partnership with the scientific community, our clinical trial program is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to treat. Our pivotal HCV clinical trials for faldaprevir and deleobuvir are comprised of two multi-trial programs, STARTVerso™ (NCT01343888, NCT01297270, NCT01358864, NCT01399619) and HCVerso®.

Faldaprevir (BI 201335) is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. STARTVerso™ is a multi-study Phase 3 trial program that evaluates faldaprevir combined with
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Actavis plc (NYSE: ACT ) ... complete response letter from the U.S. Food and ... (NDA) for the fixed-dose combination (FDC) of nebivolol ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... of a complete response letter, Actavis remains committed ...
(Date:12/24/2014)... 24, 2014  The International Trade Commission (ITC) issued its ... BMC Medical. In a notice issued on December 23, the ... patent on its humidifier was invalid. BMC President, ... "We are very excited with the ITC,s decision in this ... have taken since the very beginning on the key patents ...
(Date:12/24/2014)... Dec. 23, 2014 PuraMed BioScience®, Inc., (OTC ... (OTC) medicinal and healthcare products, announced it received the ... a hemp-based, advanced headache relief product, for planned distribution ... Colorado , Washington State ... With the MigraPure H Advanced headache relief gel formulation ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... BEND, Oregon, December 15 Bend Research Inc. announced,today that its ... used in technologies developed by the firm to enhance the oral,bioavailability ... clients may now reference a Type V Drug Master File (DMF),for ... , "We,re excited about this new development ...
... , MALVERN, Pa., Dec. 14 Fujirebio Diagnostics Inc., ... the Year by the Eastern Technology Council at a gala ... December 3, 2009. , The Eastern Technology Council ... association. Known as "The Academy Awards" of the Technology and ...
Cached Medicine Technology:Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient 2Fujirebio Diagnostics Named Life Sciences Company of the Year 2
(Date:12/26/2014)... (PRWEB) December 26, 2014 “Many people ... with personal injury claim issues and phone calls with ... released an article featuring their free eBook on ... helpful eBook on pedestrian and bicycle auto accident claims ... is fully capable of professionally handling their case while ...
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue ... reports. According to an Order issued in the U.S. ... the Court will convene an open conference on January ... and United States Courthouse in West Palm Beach, Florida. ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Very sick children with complex chronic illnesses can receive effective, ... "medical home," with easy access to a team of dedicated ... less likely to become seriously ill and need either hospitalization ... treatment at an enhanced medical home clinic at the University ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... Watch Policy against preparing for Bird flu epidemic may be ... taking intensified precautionary measures for curbing in case of a ... India to beef up // its precautionary measures to ... threat this winter from china due to spread from migratory ...
... Virginia Commonwealth University have found that increased levels of ... responsible for increasing the risk of heart disease in ... inflammation of the supporting tissue that surrounds the teeth. ... host of diseases including diabetes and cardiovascular disease. The ...
... funded survey indicates that the ageing population in Kerala which ... a day and most are non-vegetarians. ,Almost ... in Kerala eat three meals a day, according to ‘Kerala ... some interesting problem with the health of the elderly population. ...
... facing a new threat of bird flu panic fallowing ... ministry is undergoing tests for isolating// and identification of ... were no earlier reports on isolation of the virulent ... are confident that the strain is not spread from ...
... says that squinting at your computer screens is bad for the ... to eye strain, irritation and tearing // . Researchers at the ... they put themselves at risk for dry eye. ,"People ... display, and that squinting makes the blink rate go way down," ...
... in the December 1, 2005, issue of the International ... of radiation therapy // and chemotherapy could ... ,The journal, which is the official publication ... (ASTRO), adds that this combination approach is better than ...
Cached Medicine News:Health News:Severe Gum Disease Triples Heart Disease Risk 2Health News:Three meals daily Keeps 'Kerala's elderly Healthy 2Health News:Radiation And Chemotherapy, A Better Option For Head And Neck Cancer 2
ISI Self-Supporting Arm Table offers the easy accessibility for surgeons, technicians and equipment during upper extremity surgeries....
MagPrep® Streptavidin Beads are encapsulated super-paramagnetic polystyrol particles coated with streptavidin. The beads have a diameter of 1 m and are provided as a stabilized aqueous suspensio...
BioVintages Biotin-Trapper™ Streptavidin Magnetic Beads (1 mm - 2 mm) are designed for single-step capture of biotinylated molecules such as DNA, RNA or protein from cell lysates or hybridizatio...
QuantumPlex is a bead kit for multiple analyte-detection research applications in flow cytometry. The beads may be analyzed with any standard cytometer and do not require the use of specialized softw...
Medicine Products: